{"id":"vehicle-of-zylet","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Conjunctival erythema"},{"rate":null,"effect":"Increased intraocular pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zylet is a combination ophthalmic suspension containing a corticosteroid (loteprednol etabonate) and an aminoglycoside antibiotic (tobramycin). The vehicle itself is not pharmacologically active but is formulated to provide appropriate viscosity, stability, and ocular bioavailability for topical eye drop administration. The vehicle enables sustained contact with ocular tissues and optimal therapeutic delivery of the active agents.","oneSentence":"The vehicle of Zylet is an inert pharmaceutical formulation base that serves as the delivery medium for the active pharmaceutical ingredients loteprednol etabonate and tobramycin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:15:07.364Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Steroid-responsive inflammatory ocular conditions where bacterial infection or risk of bacterial infection exists"}]},"trialDetails":[{"nctId":"NCT00705159","phase":"PHASE4","title":"Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2008-06","conditions":"Conjunctivitis","enrollment":137},{"nctId":"NCT00420628","phase":"PHASE4","title":"Pediatric Zylet Safety and Efficacy Study","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-11","conditions":"Chalazion, Hordeolum","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vehicle of Zylet","genericName":"Vehicle of Zylet","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The vehicle of Zylet is an inert pharmaceutical formulation base that serves as the delivery medium for the active pharmaceutical ingredients loteprednol etabonate and tobramycin. Used for Steroid-responsive inflammatory ocular conditions where bacterial infection or risk of bacterial infection exists.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}